Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.86
(0.51%)
CNY 7.86
(0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 364.17 Million | 548.98 Million | 584.29 Million | 425.21 Million | 661.49 Million | 806.07 Million |
| Cost of Revenue | 74.6 Million | 101.44 Million | 111.62 Million | 77.64 Million | 80.87 Million | 74.8 Million |
| Gross Profit | 289.57 Million | 447.54 Million | 472.66 Million | 347.56 Million | 580.61 Million | 731.27 Million |
| Operating Expenses | 665.62 Million | 670.46 Million | 701.91 Million | 505.68 Million | 589.45 Million | 635.65 Million |
| Selling, General and Administrative Expenses | 243.77 Million | 276.08 Million | 299.55 Million | 245.28 Million | 412.83 Million | 501.18 Million |
| Research and Development Expenses | 412.26 Million | 362.81 Million | 362.5 Million | 243.67 Million | 160.73 Million | 121.41 Million |
| Other Expenses | -3.27 Million | -97.36 Thousand | 467.69 Thousand | -6.64 Million | 2.81 Million | 1.26 Million |
| Cost and Expenses | 730.33 Million | 771.91 Million | 813.54 Million | 583.32 Million | 670.33 Million | 710.45 Million |
| Operating Income | -372.36 Million | -242.97 Million | -213.21 Million | -155.26 Million | 20.34 Million | 149.71 Million |
| Interest Expense | 1.34 Million | 357.88 Thousand | 651.19 Thousand | 1.02 Million | 1.03 Million | 609.61 Thousand |
| Income Tax Expense | 32.44 Million | -46.06 Million | -75.55 Million | -27.13 Million | -7.14 Million | 16.92 Million |
| Earnings before Tax | -366.44 Million | -243.07 Million | -212.95 Million | -160.15 Million | 20.15 Million | 150.98 Million |
| Net Income | -398.89 Million | -197 Million | -137.4 Million | -133.01 Million | 27.29 Million | 134.05 Million |
| Earnings Per Share Basic | -0.83 | -0.41 | -0.29 | -0.28 | 0.06 | 0.28 |
| Earnings Per Share Diluted | -0.83 | -0.41 | -0.29 | -0.28 | 0.06 | 0.28 |
| Weighted Average Shares Outstanding | 477.77 Million | 475.35 Million | 473.79 Million | 469.65 Million | 469.65 Million | 476.7 Million |
| Weighted Average Shares Outstanding (Diluted) | 477.77 Million | 475.35 Million | 473.79 Million | 469.65 Million | 469.65 Million | 478.77 Million |
| Gross Margin | 0.80 | 0.82 | 0.81 | 0.82 | 0.88 | 0.91 |
| EBIT Margin | -0.91 | -0.33 | -0.29 | -0.26 | 0.08 | 0.22 |
| Profit Margin | -1.10 | -0.36 | -0.24 | -0.31 | 0.04 | 0.17 |
| EBITDA | -332.65 Million | -208.72 Million | -175.2 Million | -123.53 Million | 52.38 Million | 110.87 Million |
| Earnings Before Tax Margin | -1.02 | -0.44 | -0.36 | -0.37 | 0.03 | 0.19 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 78.59 Million | 86.54 Million | 93.71 Million | 89.42 Million | 359.96 Million | 105.08 Million |
| Cost of Revenue | 15.24 Million | 21.02 Million | 15.46 Million | 19.94 Million | 85.25 Million | 21.35 Million |
| Gross Profit | 63.35 Million | 65.52 Million | 78.25 Million | 69.48 Million | 274.7 Million | 83.72 Million |
| Operating Expenses | 70.5 Million | 67.21 Million | 82.52 Million | 256.63 Million | 647.07 Million | 115.06 Million |
| Selling, General and Administrative Expenses | 85.58 Million | 43.33 Million | 51.83 Million | 89.24 Million | - | 78.32 Million |
| Research and Development Expenses | 19.39 Million | 23.87 Million | 30.69 Million | 156.52 Million | - | 54.09 Million |
| Other Expenses | -34.46 Million | -7150.00 | -501.29 Thousand | -10.85 Million | -8.81 Million | -163.62 Thousand |
| Cost and Expenses | 85.75 Million | 88.23 Million | 97.98 Million | 276.57 Million | 732.33 Million | 136.41 Million |
| Operating Income | -5.95 Million | -1.68 Million | -4.26 Million | -187.14 Million | -372.36 Million | -29.7 Million |
| Interest Expense | 64.23 Thousand | 256.77 Thousand | 276.13 Thousand | 405.63 Thousand | 1.16 Million | 471.75 Thousand |
| Income Tax Expense | -68.8 Thousand | 687.17 | 65.86 Thousand | 30.72 Million | 32.44 Million | 1.67 Million |
| Earnings before Tax | -5.94 Million | 457.46 Thousand | -3.7 Million | -182.84 Million | -366.44 Million | -29.86 Million |
| Net Income | -5.94 Million | 346.38 Thousand | -3.76 Million | -213.92 Million | -398.89 Million | -31.53 Million |
| Earnings Per Share Basic | -0.01 | 0.00 | -0.01 | -0.45 | - | -0.07 |
| Earnings Per Share Diluted | -0.01 | 0.00 | -0.01 | -0.45 | - | -0.07 |
| Weighted Average Shares Outstanding | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million | 477.77 Million |
| Gross Margin | 0.81 | 0.76 | 0.84 | 0.78 | 0.76 | 0.80 |
| EBIT Margin | -0.07 | 0.07 | -0.04 | -2.01 | - | -0.29 |
| Profit Margin | -0.08 | 0.00 | -0.04 | -2.39 | -1.11 | -0.30 |
| EBITDA | -5.87 Million | 6.22 Million | -3.54 Million | -179.34 Million | - | -30.89 Million |
| Earnings Before Tax Margin | -0.08 | -0.02 | -0.05 | -2.09 | -1.03 | -0.28 |
NCKAF
SSC
RSDFIN
FC
ACS
8114